Pediatric chest wall Ewing's sarcoma
Autor: | Manjit S. Bains, Michael P. LaQuaglia, David J. Hass, Paul A. Meyers, Nicholas C. Saenz, Smitha V. Gollamudi, Norma Wollner |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Sarcoma Ewing Multimodality Therapy Biopsy medicine Humans Child Neoadjuvant therapy Retrospective Studies Chemotherapy medicine.diagnostic_test business.industry Ewing's sarcoma Radiotherapy Dosage Retrospective cohort study General Medicine Thoracic Neoplasms Prognosis medicine.disease Survival Analysis Surgery Radiation therapy Chemotherapy Adjuvant Child Preschool Pediatrics Perinatology and Child Health Female Radiotherapy Adjuvant Sarcoma Neoplasm Recurrence Local business |
Zdroj: | Journal of Pediatric Surgery. 35:550-555 |
ISSN: | 0022-3468 |
DOI: | 10.1053/jpsu.2000.0350550 |
Popis: | Background: Chest wall tumors of primitive neuroectodermal origin (PNET, Ewing's sarcoma [ES]) are rare and have a poor prognosis. Multimodality therapy has improved survival results, and long-term survival is possible. Whether adjuvant radiation therapy is uniformly beneficial remains unclear. Methods: A retrospective analysis of the authors' institutional experience between 1979 and 1998 was performed. Results: Twenty consecutive patients with PNET-ES of the chest wall were identified. The median age was 12 years (range, 2.5 to 21 years). Median follow-up was 3 years (range, 7 months to 19.4 years). Seven patients presented with a mass, 12 with pain, 1 with respiratory distress, and 1 with a neuropathy. Initial therapy consisted of biopsy and neoadjuvant chemotherapy followed by chest wall resection in 12 patients. Of the remaining 8 patients, 6 underwent biopsy, followed by chest wall resection and adjuvant chemotherapy, 1 underwent biopsy, chemotherapy, and resection of a lung nodule, and 1 underwent biopsy, chemotherapy, and a laminectomy and decompression procedure. All 20 patients were included in institutional-based trials using multiagent chemotherapy. Fifteen patients received radiation therapy with a median dose of 3,000 cGy. At last follow-up, 11 patients are alive and disease free, with a median survival of 7.5 years (range, 7 months to 19.4 years). Seven of 11 (64%) survivors had neoadjuvant therapy followed by chest wall resection. Seven of 11 (64%) survivors had radiation therapy. There was no surgical mortality. Twelve patients had treatment-related complications, 3 of which were related to surgical resection. There were no survivors among patients with recurrent disease. Three of the patients who died of disease had both local and distant recurrences, 4 patients had distant recurrence only, and one patient had local recurrence only. Only 4 of 9 (44%) patients who died were treated initially with chemotherapy followed by chest wall resection. All but 1 of those that died (89%) received initial radiation therapy. All 9 patients who did not survive received additional salvage radiotherapy as well. Conclusions: Long-term survival is possible with ES-PNET after complete chest wall resection. This may be facilitated by neoadjuvant chemotherapy. Long-term survival without radiation therapy is possible, and consideration of radiation therapy should be made on a case-by-case basis. J Pediatr Surg 35:550-555. Copyright © 2000 by W.B. Saunders Company. |
Databáze: | OpenAIRE |
Externí odkaz: |